COVID-19 大流行后儿童呼吸道合胞病毒住院与呼吸支持
这项横断面研究基于美国 48 家独立儿童医院的 PHIS 数据库,纳入 2017 年 7 月 1 日至 2023 年 6 月 30 日≤5 岁 RSV 患儿共 288 816 例。大流行后(2022–2023 季)RSV 就诊数从大流行前 39 698 例增至 94 347 例(P < .001),住院数增加 86.7%(50 619 vs 27 114,P < .001);进展性呼吸支持使用增加 70.1%(9094 vs 5340,P < .001)。与大流行前相比,2022–2023 季患儿年龄更大、合并症更少,且各呼吸支持模式下合并症比例均更低。作者认为这些趋势可能为未来 RSV 季新型疫苗分配提供参考。
要点
- 大流行后 RSV 就诊从 39 698 例增至 94 347 例(P < .001),住院增加 86.7%(50 619 vs 27 114,P < .001)。
- 2022–2023 季进展性呼吸支持使用增加 70.1%(9094 vs 5340,P < .001)。
- 需 HFNC 或 NIV 的患儿比大流行前更大:HFNC 中位年龄 6.9 vs 4.6 个月,NIV 6.0 vs 4.3 个月。
- 住院患儿合并症比例下降(17.6% vs 21.8%,P < .001),各支持模式下合并症均更少(HFNC 14.9% vs 19.1%;NIV 22.0% vs 28.5%;有创机械通气 30.5% vs 38.0%;P < .001)。
- 2022–2023 季住院患儿中位年龄 11.3 个月,大于大流行前的 6.8 个月(P < .001)。
适用人群与场景
- 美国 48 家独立儿童医院(PHIS 数据库)中≤5 岁、因 RSV 就诊的儿童,时间跨度 2017 年 7 月 1 日至 2023 年 6 月 30 日。
- 大流行前 RSV 季定义为 2017–2018、2018–2019、2019–2020 季;大流行后季定义为 2022–2023 季;每季为 7 月 1 日至次年 6 月 30 日。
研究设计与关键结果
- 横断面研究,纳入 288 816 例≤5 岁 RSV 患儿(中位年龄 8.9 个月,IQR 3.3–21.5;男性 159 348 例,55.2%),来自美国 48 家独立儿童医院。
- 大流行后 RSV 就诊数从大流行前 39 698 例增至 94 347 例(P < .001),住院数增加 86.7%(50 619 vs 27 114,P < .001)。
- 2022–2023 季患儿中位年龄 11.3 个月(IQR 4.1–26.6)vs 大流行前 6.8 个月(IQR 2.6–16.8),P < .001;住院患儿合并症比例 17.6% vs 21.8%,P < .001。
- 2022–2023 季进展性呼吸支持使用增加 70.1%(9094 vs 5340,P < .001)。
- 需 HFNC 的患儿中位年龄 6.9 个月(IQR 2.7–16.0)vs 大流行前 4.6 个月(IQR 2.0–11.7);需 NIV 的患儿中位年龄 6.0 个月(IQR 2.1–16.5)vs 4.3 个月(IQR 1.9–11.9)。
- 大流行后各呼吸支持模式下合并症比例均更低:HFNC 14.9% vs 19.1%,NIV 22.0% vs 28.5%,有创机械通气 30.5% vs 38.0%(P < .001)。
证据类型、等级与局限
- 证据类型:横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些临床趋势可能为未来 RSV 季新型疫苗分配提供参考,以降低总体负担。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: After the COVID-19 pandemic, there was a surge of pediatric respiratory syncytial virus (RSV) infections, but national data on hospitalization and intensive care unit use and advanced respiratory support modalities have not been reported.
OBJECTIVE: To analyze demographics, respiratory support modes, and clinical outcomes of children with RSV infections at tertiary pediatric hospitals from 2017 to 2023.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study evaluated children from 48 freestanding US children's hospitals registered in the Pediatric Health Information System (PHIS) database. Patients 5 years or younger with RSV from July 1, 2017, to June 30, 2023, were included. Each season was defined from July 1 to June 30. Prepandemic RSV seasons included 2017 to 2018, 2018 to 2019, and 2019 to 2020. The postpandemic season was delineated as 2022 to 2023.
EXPOSURE: Hospital presentation with RSV infection.
MAIN OUTCOMES AND MEASURES: Data on emergency department presentations, hospital or intensive care unit admission and length of stay, demographics, respiratory support use, mortality, and cardiopulmonary resuscitation were analyzed. Postpandemic season data were compared with prepandemic seasonal averages.
RESULTS: A total of 288 816 children aged 5 years or younger (median [IQR] age, 8.9 [3.3-21.5] months; 159 348 [55.2%] male) presented to 48 US children's hospitals with RSV from July 1, 2017, to June 30, 2023. Respiratory syncytial virus hospital presentations increased from 39 698 before the COVID-19 pandemic to 94 347 after the pandemic (P < .001), with 86.7% more hospitalizations than before the pandemic (50 619 vs 27 114; P < .001). In 2022 to 2023, children were older (median [IQR] age, 11.3 [4.1-26.6] months vs 6.8 [2.6-16.8] months; P < .001) and had fewer comorbidities (17.6% vs 21.8% of hospitalized patients; P < .001) than during prepandemic seasons. Advanced respiratory support use increased 70.1% in 2022 to 2023 (9094 vs 5340; P < .001), and children requiring high-flow nasal cannula (HFNC) or noninvasive ventilation (NIV) were older than during prepandemic seasons (median [IQR] age for HFNC, 6.9 [2.7-16.0] months vs 4.6 [2.0-11.7] months; for NIV, 6.0 [2.1-16.5] months vs 4.3 [1.9-11.9] months). Comorbid conditions were less frequent after the pandemic across all respiratory support modalities (HFNC, 14.9% vs 19.1%, NIV, 22.0% vs 28.5%, invasive mechanical ventilation, 30.5% vs 38.0%; P < .001).
CONCLUSIONS AND RELEVANCE: This cross-sectional study identified a postpandemic pediatric RSV surge that resulted in markedly increased hospital volumes and advanced respiratory support needs in older children with fewer comorbidities than prepandemic seasons. These clinical trends may inform novel vaccine allocation to reduce the overall burden during future RSV seasons.
参考来源
- Winthrop ZA, Perez JM, Staffa SJ, et al. Pediatric Respiratory Syncytial Virus Hospitalizations and Respiratory Support After the COVID-19 Pandemic. JAMA Netw Open. 2024. PMID: 38869896. doi:10.1001/jamanetworkopen.2024.16852
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。